| Ytd | -15.43% | |
| 1y | 2.77% |
| Open | 18.23 | Prev Close | 17.97 | Low | 17.45 | High | 18.41 | Mkt Cap | 1.92B |
| Vol | 3.36M | Avg Vol | 3.17M | EPS | 0.35 | P/E | 52.00 | Forward P/E | 6.68 |
| Beta | 0.20 | Short Ratio | 8.99 | Inst. Own | 99.04% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-05 | 50-d Avg | 18.09 | 200-d Avg | 19.69 | 1yr Est | 22.00 |
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
The U.S. Food and Drug Administration (FDA) accepted on Tuesday Sarepta Therapeutics Inc.'s (NASDAQ:
FDA accepts Sarepta's filings seeking traditional approval for AMONDYS 45 and VYONDYS 53, with a
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), the leader in precision genetic medicine for rare disease
– Accepted for review with target action date of February 28, 2027Sarepta Therapeutics, Inc. (NASDAQ
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
U.S. stocks traded higher by midday Wednesday, with semiconductor equipment names and small caps lea